The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.
 
Richard Tuli
No Relationships to Disclose
 
Fergus Keane
No Relationships to Disclose
 
Joshua David Schoenfeld
No Relationships to Disclose
 
Catherine O'Connor
No Relationships to Disclose
 
Charlie White
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Carly Schwartz
No Relationships to Disclose
 
Mary Larsen
No Relationships to Disclose
 
Robin Brenner
No Relationships to Disclose
 
Wungki Park
Consulting or Advisory Role - Cerner Enviza; onconic therapeutics
Research Funding - Astellas Pharma (Inst); Merck (Inst)
 
Nicholas Nissen
No Relationships to Disclose
 
Alice Zervoudakis
No Relationships to Disclose
 
Anna M. Varghese
Consulting or Advisory Role - Lilly (I); Roche (I)
Research Funding - BioMed Valley Discoveries; Bristol-Myers Squibb; Illumina (I); Lilly; Silenseed; Verastem
Travel, Accommodations, Expenses - Roche (I)
 
Kenneth H. Yu
Consulting or Advisory Role - Ipsen
Research Funding - General Oncology (Inst); Ipsen; OncoC4 (Inst); Senhwa Biosciences (Inst)
 
Marinela Capanu
No Relationships to Disclose
 
Santosha Vardhana
Honoraria - Agios
Consulting or Advisory Role - ADC Therapeutics; Immunai
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Faraday Pharmaceuticals; Ipsen; Merus; Novartis; Pancreatic Cancer Action Network; Perthera; Valar Labs; Varian Medical Systems
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst)
Travel, Accommodations, Expenses - Halozyme
Other Relationship - FibroGen
 
Marsha Reyngold
No Relationships to Disclose
 
Christopher H. Crane
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - AstraZeneca; Autem Medical (I); Boehringer Ingelheim; Eisai (I); Exelixis (I); Genentech/Roche (I); Helio Health (I); Incyte (I); Ipsen; Merck; Novartis; QED Therapeutics (I); Yiviva (I); Yiviva (I)
Research Funding - Arcus Ventures (Inst); AstraZeneca/MedImmune (Inst); BioNTech (Inst); Bristol Myers Squibb (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Helsinn Healthcare (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); Roche (Inst); Yiviva (Inst)
(OPTIONAL) Uncompensated Relationships - Thetis Pharma